Predict your next investment

Corporation
HEALTHCARE | Drug Development
cognatebioservices.com

See what CB Insights has to offer

Founded Year

2002

Stage

Acquired | Acquired

Valuation

$0000 

About Cognate BioServices

Cognate BioServices provides a range of commercialization services to regenerative medicine, cellular immunotherapy, and advanced cell therapy companies.On February 17th, 2021, Cognate BioServices was acquired by Charles River Laboratories at a valuation of $875M.

Cognate BioServices Headquarter Location

4600 East Shelby Drive Suite 108

Memphis, Tennessee, 38118,

United States

901-541-9800

Latest Cognate BioServices News

Assessment of the Viral Vectors and Plasmid DNA Global Market to 2030 - Featuring Cobra Biologics, Mylan, FUJIFILM Diosynth Biotechnologies and Thermo Fisher Scientific Among Others

Jan 14, 2022

News provided by Share this article Share this article The global viral vectors & plasmid DNA market is expected to grow from $0.55 billion in 2020 to $0.64 billion in 2021 at a compound annual growth rate (CAGR) of 16.4%. The growth is mainly due to the outbreak of COVID-19 and requires targeted delivery of the drug to treat affected patients. The number of cases has been increasing resulting in a surge in demand for viral vectors & plasmid DNA. The market is expected to reach $1.34 billion in 2025 at a CAGR of 20%. The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services. The viral vectors & plasmid DNA are used for the delivery of cellular therapies, like gene therapy and immunotherapy, and also for treating some viral infections. The viral vectors & plasmid DNA are used for formulation development in research and development labs. The viral vectors are genetically engineered viruses carrying viral RNA or DNA that is non-infectious but still contain viral promoters and transgene. The plasmid DNA is a double-stranded extrachromosomal and circular DNA sequence that is capable of replication using the host cell's replication system. The viral vectors & plasmid DNA market covered in this report is segmented by product into plasmid DNA, viral vectors and by applications into gene and cancer therapies, viral infections, immunotherapy, formulation development, others. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The unaffordable cost of gene therapies is a major challenge in the viral vectors & plasmid DNA market. The prices of gene therapies range between $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. In January 2020, Cognate Bioservices Inc, a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, specialized in providing manufacturing services for plasmid DNA and viral vector, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. The rise in the global incidence of cancer is driving the viral vector & plasmid DNA market. According to American cancer society 2020, an estimated 1.8 million new cancer cases are diagnosed and 606,520 cancer deaths in the United States. The rise in the global incidence of cancer has boosted the demand for the viral vectors and plasmid DNA market. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. Key Topics Covered: 3. Viral Vectors & Plasmid DNA Market Trends and Strategies 4. Impact Of COVID-19 On Viral Vectors & Plasmid DNA 5. Viral Vectors & Plasmid DNA Market Size and Growth 5.1. Global Viral Vectors & Plasmid DNA Historic Market, 2015-2020, $ Billion 5.1.1. Drivers Of the Market 5.1.2. Restraints On the Market 5.2. Global Viral Vectors & Plasmid DNA Forecast Market, 2020-2025F, 2030F, $ Billion 5.2.1. Drivers Of the Market 5.2.2. Restraints On the Market 6. Viral Vectors & Plasmid DNA Market Segmentation 6.1. Global Viral Vectors & Plasmid DNA Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion Plasmid DNA Viral Vectors 6.2. Global Viral Vectors & Plasmid DNA Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion Gene and Cancer therapies

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cognate BioServices

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cognate BioServices is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Cognate BioServices Patents

Cognate BioServices has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/8/2007

2/9/2016

Stem cells, Transcription factors, Clusters of differentiation, Cell biology, Biotechnology

Grant

Application Date

1/8/2007

Grant Date

2/9/2016

Title

Related Topics

Stem cells, Transcription factors, Clusters of differentiation, Cell biology, Biotechnology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.